Combined MET and PD-L1 inhibition shows promise in MET-driven metastatic papillary renal cancer

Advanced papillary renal cancer (PRC) has a poor prognosis with few treatment options available. Approximately 30% of patients with this disease present alterations in the MET gene that encodes a hepatocyte growth factor receptor. Mutations in this gene are implicated in disease progression and can also contribute to cancer drug resistance. While the association of MET mutations with the development of this kidney cancer subtype has been well described, the effect of specifically targeting this gene is unclear.

Leave A Comment

Your email address will not be published. Required fields are marked *